1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully

10/19/2021 | 01:30am EDT

Ascelia Pharma AB announced that the last patient visit has been completed in the study to evaluate the effect of food intake on the absorption of Orviglance (Mangoral). This Food Effect Study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authorization package to the health authorities including FDA and EMA. Orviglance is Ascelia Pharma's oral investigational MRI imaging agent used in the visualization of cancer in the liver and is currently in Phase 3 development. The Food Effect Study is designed to assess whether the current requirement to fast before patients are given Orviglance is strictly necessary. A potential removal or adjustment of the fasting requirement will simplify and provide convenience for patients using Orviglance. More specifically, the objective of the Food Effect study is to evaluate the effect of food intake on pharmacokinetics, pharmacodynamics and safety of Orviglance. In this crossover study, Orviglance was administered in 24 healthy volunteers in fasting condition versus two conditions with food intake (snack or full meal). Preliminary data indicate that Orviglance has been well tolerated in the study. Final results of the Food Effect Study are expected within 4 months.


© S&P Capital IQ 2021
All news about ASCELIA PHARMA AB (PUBL)
05/11TRANSCRIPT : Ascelia Pharma AB, Q1 2022 Earnings Call, May 11, 2022
CI
05/11QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals
AQ
05/11Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver..
AQ
05/10Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is N..
CI
05/05Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
AQ
05/05Ascelia Pharma AB Announces Resignation of Bo Jesper Hansen as Board Member
CI
04/11Ascelia Pharma publishes Annual Report for 2021
AQ
04/05Notice of annual general meeting in ascelia pharma ab
AQ
04/01CFO Kristian Borbos to leave Ascelia Pharma
AQ
More news
Financials
Sales 2022 - - -
Net income 2022 -155 M -15,6 M -15,6 M
Net cash 2022 104 M 10,4 M 10,4 M
P/E ratio 2022 -4,57x
Yield 2022 -
Capitalization 692 M 69,4 M 69,4 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 21
Free-Float 83,7%
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 20,55 SEK
Average target price 61,50 SEK
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-31.16%69
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567